HIF-1α mRNA gene expression levels in improved diagnosis of early stages of prostate cancer

Biomarkers

Volumn 13, Issue 7-8, 2008, Pages 680-691

  Pipinikas, Christodoulos P ^a   Carter, Nicholas D ^a   Corbishley, Catherine M ^a   Fenske, Christiane D ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Diagnostic marker; HIF 1alpha; ; Prostate cancer; Prostate specific antigen; Quantitative RT PCR; ROC curve analysis

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; DOWN REGULATION; EARLY CANCER; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UPREGULATION; BLOOD; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROSTATE TUMOR; ROC CURVE; TIME;

DISEASE PROGRESSION; EARLY DETECTION OF CANCER; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; ROC CURVE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 58049194196     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500802591992     Document Type: Article

References (27)

1. Bunting, PS. (1995) A guide to the interpretation of serum prostate specific antigen levels. Clinical Biochemistry, 28, pp. 221-241.
2. Carter, HB. (2004) Prostate cancers in men with low PSA levels - must we find them?. New England Journal of Medicine, 350, pp. 2292-2294.
3. Greenlee, RT, Murray, T., Bolden, S. and Wingo, PA. (2000) Cancer statistics 2000, pp. 7-33. Cancer Journal for Clinicians 50, CA
4. Hanahan, D. and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, pp. 353-364.
5. Hopfl, G., Ogunshola, O. and Gassmann, M. (2004) HIFs and tumours - causes and consequences. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 286, p. R608.
6. Johnsen, M., Lund, LR, Romer, J., Almholt, K. and Danø, K. (1998) Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation. Current Opinions in Cell Biology, 10, pp. 667-671.
7. Kiriakidis, S., Esteban, MA and Maxwell, PH. (2007) Genetic insights into hypoxia-inducible factor (HIF) pathway. Advances in Enzyme Regulation, 47, pp. 288-306.
8. Krumholtz, JS, Carvalhal, GF, Ramos, CG, Smith, DS, Thorson, P., Yan, Y., Humphrey, PA, Roehl, KA and Catalona, WJ. (2002) Prostate-specific antigen cut-off of 2.6 ng/ml for prostate cancer screening is associated with favourable pathologic tumour features. Urology, 60, pp. 469-474.
9. Maxwell, PH. (2005) The HIF pathway in cancer. Seminars in Cell and Developmental Biology, 16, pp. 523-530.
10. Maxwell, PH, Dachs, GU, Gleadle, JM, Nicholls, LG, Harris, AL, Stratford, IJ, Hankinson, O., Pugh, CW and Ratcliffe, PJ. (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumours and influences both angiogenesis and tumour growth. Proceedings of the National Academy of Sciences USA, 94, pp. 8104-8109.
11. Mikolajczyk, SD, Song, Y., Wong, JR, Matson, RS and Rittenhouse, HG. (2004) Are multiple markers the future of prostate cancer diagnostics?. Clinical Biochemistry, 37, pp. 519-528.
12. Pfaffl, MW. (2004) Quantification strategies in real-time PCR. A-Z of quantitative PCR, pp. 79-120. International University Line; Chapter 3, La Jolla, CA, USA
13. Pinthus, JH, Pacik, D. and Ramon, J. (2007) Diagnosis of prostate cancer. Recent Results in Cancer Research, 175, pp. 83-89.
14. Pipinikas, CP, Nair, SB, Kirby, RS, Carter, ND and Fenske, CD. (2007) Measurement of blood E2F3 mRNA in prostate cancer by quantitative RT-PCR - a preliminary study. Biomarkers, 12, pp. 541-557.
15. Punglia, RS, D'Amico, AV, Catalona, WJ, Roehl, KA and Kuntz, KM. (2003) Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. New England Journal of Medicine, 349, pp. 335-342.
16. Schrader, FH and Kranse, R. (2003) Verification bias and the prostate-specific antigen test - is there a case for a lower threshold for biopsy?. New England Journal of Medicine, 349, pp. 393-395.
17. Semenza, GL. (2000) HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. Journal of Applied Physiology, 88, pp. 1474-1480.
18. Semenza, GL. (2000) HIF-1 and human disease: One highly involved factor. Genes and Development, 14, pp. 1983-1991.
19. Semenza, GL. (2002) HIF-1 and tumour progression: Pathophysiology and therapeutics. Trends in Molecular Medicine, 8, p. S62.
20. Semenza, GL. (2003) Targeting the HIF-1 for cancer therapy. Nature Reviews Cancer, 3, pp. 721-732.
21. Stohrer, M., Boucher, Y., Stangassinger, M. and Jain, K. (2000) Oncotic pressure in solid tumours is elevated. Cancer Research, 60, pp. 4251-4255.
22. Takeuchi, T., Hisanaga, M., Nagao, M., Ikeda, N., Fujii, H., Koyama, F., Mukogawa, T., Matsumoto, H., Kondo, S., Takahashi, C., Noda, M. and Nakajima, Y. (2004) The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clinical Cancer Research, 10, pp. 5572-5579.
23. Thompson, IM, Pauler, DK, Goodman, PJ, Tangen, CM, Lucia, MS, Parnes, HL, Minasian, LM, Ford, LG, Lippman, SM, Crawford, ED, Crowley, JJ and Coltman Jr, CA (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level (4.0 ng per milliliter. New England Journal of Medicine, 350, pp. 2239-2246.
24. Wang, GL and Semenza, GL. (1995) Purification and characterisation of hypoxia-inducible factor 1. Journal of Biological Chemistry, 270, pp. 1230-1237.
25. Yoon, SO, Park, SJ, Yun, CH and Chung, AS. (2003) Roles of matrix metalloproteinases in tumour metastasis and angiogenesis. Journal of Biochemistry and Molecular Biology, 36, pp. 128-137.
26. Zhong, H., De Marzo, AM, Laughner, E., Lim, M., Hilton, DA, Zagzag, D., Buechler, P., Isaacs, WB, Semenza, GL and Simons, JW. (1999) Overexpression of hypoxia-inducible factor 1alpha in common cancers and their metastases. Cancer Research, 59, pp. 5830-5835.
27. Zhong, H., Semenza, GL, Simons, TW and De Marzo, AM. (2004) Up-regulation of hypoxia-inducible factor 1 alpha is an early event in prostate carcinogenesis. Cancer Detection and Prevention, 28, pp. 88-93.